Benitec grants license in Ambion settlement

By Melissa Trudinger
Tuesday, 10 August, 2004

Benitec (ASX: BLT) has settled its patent infringement case against US company Ambion, giving the company a world-wide non-exclusive licence to make and sell DNA-directed RNAi products.

The suit, which was originally filed on March 22, 2004 in the US, was settled out of court. Details of the settlement and licence have not been released by the company.

The Ambion suit was first announced in March, along with two other lawsuits filed against Nucleonics and Genscript Corporation.

"We will continue to protect our issued RNAi patent estate whilst enabling the widest usage of this important technology for both research and commercial therapeutic purposes," said CEO John McKinley in a statement.

Related News

Pig-to-human liver xenotransplant conducted in a living recipient

The case involved a 71-year-old man with hepatitis B-related cirrhosis and hepatocellular...

Inhaled form of blood thinner treats serious COVID infections

Heparin has traditionally been injected and used to treat blood clots, but the new study tested...

Next-gen therapies could treat high-grade gliomas

Government funding will enable researchers to test a suite of next-generation therapies they have...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd